Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2007-06-08
2010-12-28
Helms, Larry R. (Department: 1642)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C514S002600, C435S068100
Reexamination Certificate
active
07858745
ABSTRACT:
The invention provides methods for enhancing efficiency of prodrugs by specifically engineered enzymes with enhanced activity towards nucleoside analogs used in cancer chemotherapy, and delivering the enzymes to specific target cells in a patient. The invention also provides modified deoxycytidine kinase (dCK) mutants with such enhanced activity. Furthermore, the invention provides antibody-conjugated enzymes that can be specifically delivered to leukemic blast cells in vivo or ex vivo.
REFERENCES:
patent: 5914258 (1999-06-01), Wei et al.
patent: 6299876 (2001-10-01), Bagshawe
patent: 2001/0012835 (2001-08-01), Fine
patent: 2007/0037269 (2007-02-01), Marliere et al.
patent: 2823219 (2002-10-01), None
patent: WO 01/88106 (2001-05-01), None
patent: WO 02/083892 (2002-10-01), None
Johansson et al, Nature Structural Biology, 8: 616-619, 2001.
Sequence search result-SEQ ID No. 1 (2009).
Bergman et al., 1999, Biochem. Pharmacol. 57: 397-406.
Blackstock et al., 2001, Clin. Cancer Res. 7:3263-8.
Blakey et al., 1997, Exp. Opin. Ther. Patents, 7:966-977.
Estey et al., 1987, Leukemia 1:580-3.
Estey, 2000, Blood 96: 1670-3.
Gandhi et al., 1993, J. Clin. Oncol. 11: 116-24.
Gladstone et al., 2003, Blood, 102: 138(A).
Goan et al., 1999, Cancer Res. 59: 4204-7.
Hapke et al., 1996, Cancer Res. 56: 2343-7.
Hubert et al., 1999, Proc Natl Acad Sci USA 7:4523-8.
Iacoboni et al., 1986, J. Clin. Oncol. 4:1079-88.
Kabouridis, 2003, Trends in Biotechnology 21:498-503.
Kakihara et al., 1998, Leuk. Lymphoma 31:405-9.
Kantarjian et al., 1986, Am. J. Med. 81:387-94.
Kossman et al., 1999, Clin. Can. Res. 5:2748-55.
Knecht et al., 2002, EMBO J. 21:1873-1880.
Lotfi et al., 1999, Clin. Cancer Res. 5:2438-44.
Mansson et al., 2003, Biochem. Pharmacol. 65:237-247.
Owens et al., 1992, Cancer Res. 52:2389-93.
Plunkett et al., 1985, Semin Oncol 12:20-30.
Ruiz van Haperen et al., 1994, Cancer Res. 54: 4138-43.
Sandlie and Brekke 2003, Nat. Rev. Drug Discovery 2:52-62.
Stegmann et al., 1995, Blood 85: 1188-94.
Van Rompay, et al., 2000, Pharmacol. Ther. 87: 189-98.
Zhu et al., 2000, J. Biol. Chem. 275: 26727.
Iyidogan, Pinar, et al., “Systematic Exploration of Active Site Mutations on Human Deoxycytidine Kinase Substrate Specificity,” Biochemistry, 2008, vol. 47, pp. 4711-4720.
Konrad Manfred
Lavie Arnon
Ravandi Farhad
Helms Larry R.
McDonnell Boehnen & Hulbert & Berghoff LLP
The Board of Trustees of the University of Illinois
Yao Lei
LandOfFree
Use of specifically engineered enzymes to enhance the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of specifically engineered enzymes to enhance the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of specifically engineered enzymes to enhance the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4187873